Our long-term goal is to discover broad-spectrum antibiotics acting against potential biowarfare agents. The goal of this exploratory project is to develop a comprehensive approach to bypass the existing obstacles to drug discovery, which will include delivering active compounds into the pathogen, identifying new classes of antimicrobials, and efficient evaluation of toxicity/efficacy. Previous research in the Lewis laboratory showed that plants synthesize inhibitors of multi-drug resistant efflux pumps that can facilitate delivery of antimicrobials into microbial pathogens. Independently, the Ausubel laboratory developed a pathogenesis model that involves the killing of the nematode worm Caenorhabditis elegans by human microbial pathogens. The nematode can therefore be used as an animal model for primary screening of antimicrobials. This proposal describes experiments designed to merge the complementary technologies developed in these two laboratories to produce a novel approach to antimicrobial drug discovery.
The Specific Aims are: 1. High throughput whole-animal screen for novel antimicrobials will be developed using C. elegans infected with a variety of NIAID group A and B agents. These will include diarrheagenic E. coli, S. enterica, and a model gram-positive pathogen E. faecalis. We will also establish whether C. elegans is infected with B. anthracis and F. tularensis. The rationale of the antimicrobial assay is to monitor curing of worms infected with human pathogens, by test compounds. A liquid assay using GFP-labeled C. elegans will be developed into a high-throughput automated assay. 2. Screening for MDR inhibitors and new antimicrobials will be performed in vitro, and in vivo with infected C. elegans. A commercial synthetic compound library, and the NCI collection of extracts will be screened. Comparison of the in vitro and in vivo screens will identify possible compounds that only act in vivo (prodrugs, compounds targeting virulence or other components necessary for in vivo survival, and stimulators of innate immunity). Preliminary results show that the NCI library has hits for both direct and MDR inhibitory activity against all pathogens tested. We will focus on obtaining novel antimicrobials and MDR inhibitors acting against gram-negative pathogens. A combination of such an MDR inhibitor with an antimicrobial compound will produce a broad-spectrum antibiotic. We plan to screen 30,000 compounds/extracts in this pilot study. 3. We will purify and identify antimicrobial compounds. Active extracts will be used to isolate a pure substance. A sufficiently pure compound will be used to determine MIC with the pathogen panel, and those with high potency will be studied further. Determination of chemical structure will be performed by a combination of MS and NMR methods.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Exploratory/Developmental Grants (R21)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-IDM-A (90))
Program Officer
Alexander, William A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Northeastern University
Schools of Arts and Sciences
United States
Zip Code
Tomkiewicz, Danuta; Casadei, Gabriele; Larkins-Ford, Jonah et al. (2010) Berberine-INF55 (5-nitro-2-phenylindole) hybrid antimicrobials: effects of varying the relative orientation of the berberine and INF55 components. Antimicrob Agents Chemother 54:3219-24
Ambrus, Joseph I; Kelso, Michael J; Bremner, John B et al. (2008) Structure-activity relationships of 2-aryl-1H-indole inhibitors of the NorA efflux pump in Staphylococcus aureus. Bioorg Med Chem Lett 18:4294-7
Breger, Julia; Fuchs, Beth Burgwyn; Aperis, George et al. (2007) Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog 3:e18
Samosorn, Siritron; Bremner, John B; Ball, Anthony et al. (2006) Synthesis of functionalized 2-aryl-5-nitro-1H-indoles and their activity as bacterial NorA efflux pump inhibitors. Bioorg Med Chem 14:857-65
Belofsky, Gil; Carreno, Roberto; Lewis, Kim et al. (2006) Metabolites of the ""smoke tree"", Dalea spinosa, potentiate antibiotic activity against multidrug-resistant Staphylococcus aureus. J Nat Prod 69:261-4
Ball, Anthony R; Casadei, Gabriele; Samosorn, Siritron et al. (2006) Conjugating berberine to a multidrug efflux pump inhibitor creates an effective antimicrobial. ACS Chem Biol 1:594-600
Moy, Terence I; Ball, Anthony R; Anklesaria, Zafia et al. (2006) Identification of novel antimicrobials using a live-animal infection model. Proc Natl Acad Sci U S A 103:10414-9
Lewis, Kim; Ausubel, Frederick M (2006) Prospects for plant-derived antibacterials. Nat Biotechnol 24:1504-7